[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100510616":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":25,"responsibleParty":26,"collaborators":28,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":35,"acronym":36,"eligibilityCriteria":37,"healthyVolunteers":33,"sex":38,"minAge":39,"maxAge":25,"enrollmentInfo":40,"targetDuration":25,"studyType":43,"phases":44,"briefSummary":46,"conditions":47,"keywords":49,"overallStatus":51,"whyStopped":25,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":25},{"fullName":5,"class":6},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Uveitis Patients","EXPERIMENTAL","Uveitis Patients: intermediate, posterior or panuveitis noninfectious uveitis with Inflammatory activity requiring treatment with either one or more of the following:\n\n1. Systemic corticosteroids or periocular or intravitreal injections of corticosteroids\n2. Immunosuppressants: methotrexate, azathioprine, ciclosporine….\n3. Biotherapy: infliximab, adalimumab, tocilizumab",[13],"Diagnostic Test: care strategy",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Patients","ACTIVE_COMPARATOR","scheduled for cataract or vitreoretinal surgery",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIAGNOSTIC_TEST","care strategy","Uveitis patients:\n\n* Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection;\n* Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection;\n* Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort);\n* Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7.",[15,9],null,{"type":27,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[29],{"name":30,"class":6},"Groupe Hospitalier Pitie-Salpetriere","100510616","prospective-cohort-of-non-infectious-intermediate-posterior-or-panuveitis-100510616",false,"NCT05928754","Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS","CHRONOS","Inclusion Criteria:\n\nUVEITIS Patients:\n\n* Adult patients (≥ 18 years);\n* Non-infectious uveitis;\n* Intermediate, posterior or panuveitis;\n* Inflammatory activity requiring treatment with either one or more of the followings:\n\n  * Systemic corticosteroids or periocular or intravitreal injections of corticosteroids;\n  * Immunosuppressants: methotrexate, azathioprine, cyclosporine, etc.;\n  * Biotherapy: infliximab, adalimumab, tocilizumab;\n* Patients with health insurance;\n* Written Informed consent obtained at enrolment in the study.\n\nControl patients:\n\n* Adult patients (≥ 18 years);\n* Scheduled patients ( Non-urgente procedure) for cataract or vitreoretinal surgery;\n* Patients with health insurance;\n* Written Informed consent obtained at enrolment in the study.\n\nExclusion Criteria:\n\nUveitis Patients:\n\n* Isolated anterior uveitis ;\n* Inactive disease defined as:\n\n  * Absence of inflammatory chorioretinal and\u002For inflammatory retinal vascular lesion;\n  * Anterior chamber cell grade\\\u003C 0.5+;\n  * Vitreous haze grade \\\u003C0.5+;\n* Pregnant or breastfeeding woman at the inclusion visit;\n* Patient under legal protection (\" curatelle \" or \" tutelle \");\n* Patient denied freedom by a legal or administrative order.\n\nControl patients:\n\n* Pregnant or breastfeeding woman;\n* Unscheduled (urgent) cataract or vitreoretinal surgery;\n* Patient under legal protection (\" curatelle \" or \" tutelle \");\n* Patient denied freedom by a legal or administrative order.","ALL","18 Years",{"count":41,"type":42},2000,"ESTIMATED","INTERVENTIONAL",[45],"NA","prospective, cohort, longitudinal, multicenter, non-randomized study of patients with non-infectious posterior segment uveitis or panuveitis, with a group of control patients (scheduled for cataract or vitreoretinal surgery) and constitution of biological collection.",[48],"Non-infectious Uveitis",[50],"non-infectious uveitis","NOT_YET_RECRUITING","2023-06-26",{"date":54,"type":55},"2023-07-03","ACTUAL",{"date":57,"type":42},"2023-09",{"date":59,"type":42},"2028-08",{"name":5,"class":6}]